Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention
Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention: South Florida Center for Reducing Health Disparities
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- live in one of the three target communities
- self-identify as Haitian, Hispanic and/or Black.
- be 50-64 years old
- need at least one of the four recommended screening services as per US Preventive Service Task Force 121 guidelines as follows: never having had a HIV test b) never having had a Hepatitis C Virus (HCV) test c) not having a Pap smear in the last three years d) not having had a colonoscopy in last 10 years and/or stool-based test in the last year.
Exclusion Criteria:
- plan to move out of the community during the next six months;
- current or prior enrollment (5 five years) in any research study that involved screening for these conditions.
- Are adults unable to consent
- Are individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Home Based Screening
The participant will be receiving home-based screening tests (OraQuick Swab, OraQuick Fingerstick, Human Papillomavirus (HPV) Self-Sampling Test, Fecal Immunochemical Test) delivered by the community health worker
|
OraQuick for oral fluid HIV antibody testing
Fecal Immunochemical stool test specific for human hemoglobin
Patients will be tested for Hepatitis C infection using a fingerstick
Patients will be using swab to check for HPV infection
Patients will provided screening tests and instructed by Community Health Worker on how to perform home screening tests
|
|
Active Comparator: Clinic Based Screening
The participant will meet the Community Health Worker and will be navigated to a clinic appointment for standard screening tests
|
Patients will be navigated to a local health center for standard screening tests
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Who Are Screened for All Conditions
Time Frame: Baseline
|
As evaluated by participant self report and completed sampling kits.
Female participants are to be screened on 4 conditions: HIV, HCV, Human Papilloma Virus (HPV) and Fecal Immunochemical Testing (FIT).
Male participants are to be screened on 3 conditions: HIV, Hepatitis C Virus (HCV) and FIT.
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Percentage of Participants Completing Screening Test From Baseline to 6 Months
Time Frame: Baseline, Up to 6 months
|
As evaluated by participant self report and completed sampling kits.
Female participants are to be screened on 4 conditions: HIV, HCV, HPV and FIT.
Male participants are to be screened on 3 conditions: HIV, HCV and FIT.
|
Baseline, Up to 6 months
|
|
Median Number of Screenings Completed
Time Frame: At baseline and at 6 months
|
As evaluated by participant self report and completed sampling kits.
Female participants are to be screened on 4 conditions: HIV, HCV, HPV and FIT.
Male participants are to be screened on 3 conditions: HIV, HCV and FIT.
|
At baseline and at 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Olveen Carrasquillo, MD, University of Miami
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Slow Virus Diseases
- Hepatitis
- HIV Infections
- Hepatitis C
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
Other Study ID Numbers
- 20160023
- 1U01MD010614-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.